Healthcare & Medical Devices Global On demand · 24-48h

Global Thromboelastography (TEG) Machine Market Strategic Research Report

Global Thromboelastography (TEG) Machine Market Strategic Re…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Thromboelastography (TEG) Machine Market
$3842025
12.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Single and Double Channel, Four Channels, Others

By Application: Hospitals, Maternal and Child Health Service, Laboratory, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Haemonetics, Lepu Technology, Biomart, Medcaptain, Ud-bio, Chongqing Nanfang, WITEYE, Render, Guizhou Jinjiu Biotech, Chongqing Dingrun, Zhejiang Shengyu, Bio-zircon, WerfenLife, Framar Hemologix srl, Sienco

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 108 pages
Market size 2025
$384
Million USD
Forecast CAGR
12.9%
2025-2032
Forecast 2032
$897.8
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Thromboelastography (TEG) Machine market size is predicted to grow from US$ 384 million in 2025 to US$ 890 million in 2032; it is expected to grow at a CAGR of 12.9% from 2026 to 2032.

Thromboelastography (Thromboelastography) is a new blood viscoelastic detection system suitable for bedside detection. It uses whole blood samples to monitor the whole process of blood coagulation and fibrinolysis, which can well make up for the deficiency of traditional blood coagulation detection.

Thromboelastogram provides a general picture of coagulation function. It is an inspection item that can dynamically monitor the whole process of coagulation and fibrinolysis. It can completely describe the whole process of a blood sample from coagulation initiation, coagulation and dissolution, and help doctors quickly judge the patient"s coagulation status (high coagulation, low coagulation and fibrinolytic hyperactivity) and analyze the causes.

It is of great value in clinical evaluation of coagulation function, guidance of component transfusion, prediction of thrombosis/bleeding risk and guidance of medication.

Haemonetics, Werfenlife, Framar Hemologix SRL, Lepco Diagnostics, Sienco and so on are the main manufacturers of thromboelastography.The top five global manufacturers account for 77% of total sales.North America and Europe are the main production regions of thromboelastographs.North America accounts for 42% of the global production of thromboelastographs, ranking first in the world.Europe was next with 34 percent.North America is the world"s largest consumer region of thromboelastograms, accounting for 39% of global sales.Europe was second with 21 percent.

This report presents a comprehensive overview of the global Thromboelastography (TEG) Machine market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Single and Double Channel
  • Four Channels
  • Others

Segment by Application

  • Hospitals
  • Maternal and Child Health Service
  • Laboratory
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Thromboelastography (TEG) Machine market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospitals, Maternal and Child Health Service, Laboratory evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Thromboelastography (TEG) Machine Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 12.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$384
2025
Forecast
$897.8
2032
CAGR
12.9%
2025–2032
Regiones
5
global
Key companies
HaemoneticsLepu TechnologyBiomartMedcaptainUd-bioChongqing NanfangWITEYERender
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Single and Double ChannelFour ChannelsOthers
By Application
HospitalsMaternal and Child Health ServiceLaboratoryOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Single and Double Channel
  • 3.1.3 Four Channels
  • 3.1.4 Others
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospitals
  • 4.1.3 Maternal and Child Health Service
  • 4.1.4 Laboratory
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Haemonetics
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Lepu Technology
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Biomart
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Medcaptain
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Ud-bio
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Chongqing Nanfang
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 WITEYE
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Render
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Guizhou Jinjiu Biotech
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Chongqing Dingrun
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Zhejiang Shengyu
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Bio-zircon
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 WerfenLife
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Framar Hemologix srl
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Sienco
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Thromboelastography (TEG) Machine market?
The global Thromboelastography (TEG) Machine market is estimated at US$ 384 million in 2025 (base year) and is projected to reach US$ 890 million by 2032.
What is the forecast CAGR for the Thromboelastography (TEG) Machine market?
The market is expected to grow at a CAGR of 12.9% from 2026 to 2032, expanding from US$ 384 million in 2025 to US$ 890 million in 2032, roughly 2.3 times its base-year value.
What is Thromboelastography (TEG) Machine?
Thromboelastography (Thromboelastography) is a new blood viscoelastic detection system suitable for bedside detection. It uses whole blood samples to monitor the whole process of blood coagulation and fibrinolysis, which can well make up for the deficiency of traditional blood coagulation detection.
How is the Thromboelastography (TEG) Machine market segmented by type?
By type, the market is segmented into Single and Double Channel, Four Channels and Others.
What are the key applications of Thromboelastography (TEG) Machine?
Key applications covered include Hospitals, Maternal and Child Health Service, Laboratory and Others.
Which companies are profiled in the Thromboelastography (TEG) Machine market report?
Key players profiled include Haemonetics, Lepu Technology, Biomart, Medcaptain, Ud-bio, Chongqing Nanfang, WITEYE and Render, among 15 companies covered in total.
What geographies does the Thromboelastography (TEG) Machine market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Thromboelastography (TEG) Machine market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospitals, Maternal and Child Health Service and Laboratory, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Thromboelastography (TEG) Machine market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.